Status:
COMPLETED
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
Lead Sponsor:
Children's Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Ototoxicity
Unspecified Childhood Solid Tumor, Protocol Specific
Eligibility:
All Genders
1-18 years
Brief Summary
RATIONALE: New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably. PURPOSE: This clinic...
Detailed Description
OBJECTIVES: * Determine the optimal criteria for determination of ototoxicity in younger cancer patients treated with cisplatin. * Determine the feasibility of including ultrahigh frequency and evoke...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Planning to undergo treatment with any cisplatin-containing therapeutic regimen for cancer
- Treatment does not need to be on a COG therapeutic study
- Planning to enroll on clinical trial ACCL0431
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior cisplatin
Exclusion
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2017
Estimated Enrollment :
301 Patients enrolled
Trial Details
Trial ID
NCT00458887
Start Date
May 1 2007
End Date
February 28 2017
Last Update
March 13 2017
Active Locations (81)
Enter a location and click search to find clinical trials sorted by distance.
1
UAB Comprehensive Cancer Center
Birmingham, Alabama, United States, 35294
2
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
3
Childrens Hospital Los Angeles
Los Angeles, California, United States, 90027
4
Southern California Permanente Medical Group
Los Angeles, California, United States, 90027